Pancreatic Cancer Research

ResearcherUniversitätsklinikum AachenActive in the last 2 years

Georg J. Wiltberger

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2384-3847; OpenAlex author ID A5048565837. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 2 papers

Papers 11

  1. Prognostic impact of CRM-status on survival in patients with resected pancreatic adenocarcinoma - a dual-center cohort analysis. Last author DOI 10.1016/j.suronc.2026.102422↗
  2. Classification of Pancreatic Cancer and Normal Tissue in 2D and 3D Optical Coherence Tomography Images Using Convolutional Neural Networks: A Comparative Study. Co-author DOI 10.3390/cancers18050732↗
  3. Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms. Co-author DOI 10.1038/s41467-024-55424-2↗
  4. Stroma and lymphocytes identified by deep learning are independent predictors for survival in pancreatic cancer. Co-author DOI 10.1038/s41598-025-94362-x↗
  5. Inflammation-associated intramyocellular lipid alterations in human pancreatic cancer cachexia. Co-author DOI 10.1002/jcsm.13474↗
  6. The tumor immune microenvironment in resected treatment-naive pancreatic cancer patients with long-term survival. Co-author DOI 10.1016/j.pan.2024.08.014↗
  7. Lipocalin-2 and neutrophil activation in pancreatic cancer cachexia. Co-author DOI 10.3389/fimmu.2023.1159411↗
  8. Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. Co-author DOI 10.1038/s41388-020-01578-4↗
  9. Nerve Fibers in the Tumor Microenvironment Are Co-Localized with Lymphoid Aggregates in Pancreatic Cancer. Last author DOI 10.3390/jcm10030490↗
  10. The WNT5A/ROR2 signaling pathway in pancreatic ductal adenocarcinoma (PDAC) First author DOI 10.21203/rs.3.rs-34447/v1↗
  11. High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma. Co-author DOI 10.1093/carcin/bgz033↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lara Rosaline Heij · 5 shared papers, 2021–2025 · strength 0.74
  2. Steven W.M. Olde Damink · 4 shared papers, 2021–2024 · strength 0.57
  3. Merel R. Aberle · 4 shared papers, 2021–2024 · strength 0.57
  4. Shivan Sivakumar · 4 shared papers, 2021–2025 · strength 0.56
  5. Gregory van der Kroft · 3 shared papers, 2021–2024 · strength 0.47
  6. Xiuxiang Tan · 3 shared papers, 2021–2025 · strength 0.40
  7. Tom Luedde · 3 shared papers, 2019–2025 · strength 0.37
  8. Bas Groot Koerkamp · 2 shared papers, 2024–2025 · strength 0.37
  9. Casper H.J. van Eijck · 2 shared papers, 2024–2025 · strength 0.37
  10. Min Deng · 2 shared papers, 2023–2024 · strength 0.37
  11. Sander S. Rensen · 2 shared papers, 2023–2024 · strength 0.37
  12. Robert Grützmann · 1 shared paper, 2026 · strength 0.36
  13. Maximilian Brunner · 1 shared paper, 2026 · strength 0.36
  14. Judith de Vos‐Geelen · 2 shared papers, 2021–2025 · strength 0.29
  15. Svetlana Warkentin · 1 shared paper, 2026 · strength 0.26
  16. Mariia Druzenko · 1 shared paper, 2026 · strength 0.26
  17. Iakovos Amygdalos · 1 shared paper, 2026 · strength 0.26
  18. Sven Arke Lang · 2 shared papers, 2021 · strength 0.21
  19. Edgar Dahl · 1 shared paper, 2025 · strength 0.19
  20. Evelien J.M. de Jong · 1 shared paper, 2025 · strength 0.19
  21. Michail Doukas · 1 shared paper, 2025 · strength 0.19
  22. Wolfram Trudo Knoefel · 1 shared paper, 2025 · strength 0.19
  23. David P.J. van Dijk · 1 shared paper, 2024 · strength 0.19
  24. Casper W.F. van Eijck · 1 shared paper, 2024 · strength 0.18
  25. Yunlei Li · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.